{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:43:01Z","timestamp":1760150581686,"version":"build-2065373602"},"reference-count":44,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Associazione Italiana per la Ricerca sul Cancro (AIRC)","award":["18493"],"award-info":[{"award-number":["18493"]}]},{"name":"Department of Excellence\u2014DIMET, Universit\u00e0 del Piemonte Orientale","award":["18493"],"award-info":[{"award-number":["18493"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Data"],"abstract":"<jats:p>\u03b2-Galactosylceramidase (GALC) is a lysosomal enzyme involved in sphingolipid metabolism by removing \u03b2-galactosyl moieties from \u03b2-galactosyl ceramide and \u03b2-galactosyl sphingosine. Previous observations have shown that GALC exerts a pro-oncogenic activity in human melanoma. Here, the impact of GALC overexpression on the proteomic landscape of BRAF-mutated A2058 and A375 human melanoma cell lines was investigated by liquid chromatography\u2013tandem mass spectrometry analysis of the cell extracts. The results indicate that GALC overexpression causes the upregulation\/downregulation of 172\/99 proteins in GALC-transduced cells when compared to control cells. Gene ontology categorization of up\/down-regulated proteins indicates that GALC may modulate the protein landscape in BRAF-mutated melanoma cells by affecting various biological processes, including RNA metabolism, cell organelle fate, and intracellular redox status. Overall, these data provide further insights into the pro-oncogenic functions of the sphingolipid metabolizing enzyme GALC in human melanoma.<\/jats:p>","DOI":"10.3390\/data8120177","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T03:33:56Z","timestamp":1701056036000},"page":"177","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dataset: Impact of \u03b2-Galactosylceramidase Overexpression on the Protein Profile of Braf(V600E) Mutated Melanoma Cells"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-8136","authenticated-orcid":false,"given":"Davide","family":"Capoferri","sequence":"first","affiliation":[{"name":"Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy"}]},{"given":"Paola","family":"Chiodelli","sequence":"additional","affiliation":[{"name":"Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4996-7995","authenticated-orcid":false,"given":"Stefano","family":"Calza","sequence":"additional","affiliation":[{"name":"Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-5618","authenticated-orcid":false,"given":"Marcello","family":"Manfredi","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Piemonte Orientale, 13100 Novara, Italy"},{"name":"Center for Allergic and Autoimmune Diseases, University of Piemonte Orientale, 13100 Novara, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4398-8376","authenticated-orcid":false,"given":"Marco","family":"Presta","sequence":"additional","affiliation":[{"name":"Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy"},{"name":"Consorzio Interuniversitario Biotecnologie (CIB), Unit of Brescia, 25123 Brescia, Italy"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/jnr.23873","article-title":"Biochemical, Cell biological, pathological, and therapeutic aspects of Krabbe\u2019s disease","volume":"94","author":"Won","year":"2016","journal-title":"J. Neurosci. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/glycob\/cwab046","article-title":"Glucosylceramide and galactosylceramide, small glycosphingolipids with significant impact on health and disease","volume":"31","author":"Reza","year":"2021","journal-title":"Glycobiology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15169","DOI":"10.1073\/pnas.1105639108","article-title":"Insights into Krabbe disease from structures of galactocerebrosidase","volume":"108","author":"Deane","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41467-017-02361-y","article-title":"The mechanism of glycosphingolipid degradation revealed by a GALC-SapA complex structure","volume":"9","author":"Hill","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-19-3382","article-title":"\u03b2-Galactosylceramidase promotes melanoma growth via modulation of ceramide metabolism","volume":"80","author":"Belleri","year":"2020","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.trecan.2021.08.001","article-title":"\u03b2-Galactosylceramidase in cancer: Friend or foe?","volume":"7","author":"Presta","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cell.2013.12.015","article-title":"Dividing cells regulate their lipid composition and localization","volume":"156","author":"Muro","year":"2014","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3233\/CBM-170995","article-title":"Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer","volume":"22","author":"Liu","year":"2018","journal-title":"Cancer Biomark."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fonc.2020.00380","article-title":"GALC Triggers Tumorigenicity of Colorectal Cancer via Senescent Fibroblasts","volume":"10","author":"Yang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1194\/jlr.R031278","article-title":"Sphingolipids: Regulators of crosstalk between apoptosis and autophagy","volume":"54","author":"Young","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.advms.2023.10.004","article-title":"Ceramides and their roles in programmed cell death","volume":"68","author":"Pilatova","year":"2023","journal-title":"Adv. Med. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ruiz, E.M., Alhassan, S.A., Errami, Y., Abd Elmageed, Z.Y., Fang, J.S., Wang, G., Brooks, M.A., Abi-Rached, J.A., Kandil, E., and Zerfaoui, M. (2023). A Predictive Model of Adaptive Resistance to BRAF\/MEK Inhibitors in Melanoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098407"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"650165","DOI":"10.3389\/fonc.2021.650165","article-title":"Proteome Analysis of USP7 Substrates Revealed Its Role in Melanoma Through PI3K\/Akt\/FOXO and AMPK Pathways","volume":"11","author":"Gao","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"736438","DOI":"10.3389\/fonc.2021.736438","article-title":"Corrigendum: Proteome Analysis of USP7 Substrates Revealed Its Role in Melanoma through PI3K\/Akt\/FOXO and AMPK Pathways","volume":"11","author":"Gao","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1002\/pmic.200800169","article-title":"Proteomic analysis of membrane rafts of melanoma cells identifies protein patterns characteristic of the tumor progression stage","volume":"8","author":"Baruthio","year":"2008","journal-title":"Proteomics"},{"key":"ref_16","first-page":"6716","article-title":"Functional proteomic analysis of melanoma progression","volume":"63","author":"Bernard","year":"2003","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41416-018-0227-2","article-title":"Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis","volume":"119","author":"Krisp","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cell.2019.08.012","article-title":"Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence","volume":"179","author":"Harel","year":"2019","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1061832","DOI":"10.3389\/fonc.2022.1061832","article-title":"New panel of biomarkers to discriminate between amelanotic and melanotic metastatic melanoma","volume":"12","author":"Militaru","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1187332","DOI":"10.3389\/fimmu.2023.1187332","article-title":"Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy","volume":"14","author":"Pickering","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_21","first-page":"839","article-title":"Regulation of ERK3\/MAPK6 expression by BRAF","volume":"29","author":"Hoeflich","year":"2006","journal-title":"Int. J. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.molonc.2008.01.002","article-title":"Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas","volume":"1","author":"Kannengiesser","year":"2008","journal-title":"Mol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"22128","DOI":"10.1074\/jbc.M800271200","article-title":"Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim","volume":"283","author":"Sheridan","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/0008-5472.CAN-09-1491","article-title":"Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells","volume":"70","author":"Cui","year":"2010","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ottaviano, M., Giunta, E.F., Tortora, M., Curvietto, M., Attademo, L., Bosso, D., Cardalesi, C., Rosanova, M., De Placido, P., and Pietroluongo, E. (2021). BRAF Gene and Melanoma: Back to the Future. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073474"},{"key":"ref_26","unstructured":"Cancer Genome Atlas Network (2015). Genomic Classification of Cutaneous Melanoma. Cell, 161, 1681\u20131696."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Castellani, G., Buccarelli, M., Arasi, M.B., Rossi, S., Pisanu, M.E., Bellenghi, M., Lintas, C., and Tabolacci, C. (2023). BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. Cancers, 15.","DOI":"10.3390\/cancers15164026"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.2217\/fon-2023-0414","article-title":"COLUMBUS-AD: Phase III study of adjuvant encorafenib + binimetinib in resected stage IIB\/IIC BRAF V600-mutated melanoma","volume":"19","author":"Hauschild","year":"2023","journal-title":"Future Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/09546634.2017.1330530","article-title":"Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: A systematic review and meta-analysis","volume":"29","author":"Kim","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Capoferri, D., Chiodelli, P., Corli, M., Belleri, M., Scalvini, E., Mignani, L., Guerra, J., Grillo, E., De Giorgis, V., and Manfredi, M. (2023). The pro-oncogenic sphingolipid-metabolizing enzyme \u03b2-galactosylceramidase modulates the proteomic landscape in BRAF(V600E)-mutated human melanoma cells. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310555"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ng, M.F., Simmons, J.L., and Boyle, G.M. (2022). Heterogeneity in Melanoma. Cancers, 14.","DOI":"10.3390\/cancers14123030"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lee, D., Park, Y., and Kim, S. (2021). Towards multi-omics characterization of tumor heterogeneity: A comprehensive review of statistical and machine learning approaches. Brief. Bioinform., 22.","DOI":"10.1093\/bib\/bbaa188"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.semcancer.2019.06.014","article-title":"The \u201c-OMICS\u201d facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers","volume":"59","author":"Donnelly","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","article-title":"Intratumor and Intertumor Heterogeneity in Melanoma","volume":"10","author":"Grzywa","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bjc.2012.581","article-title":"Cancer heterogeneity: Implications for targeted therapeutics","volume":"108","author":"Fisher","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"iyad031","DOI":"10.1093\/genetics\/iyad031","article-title":"The Gene Ontology knowledgebase in 2023","volume":"224","author":"Aleksander","year":"2023","journal-title":"Genetics"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/pro.4218","article-title":"PANTHER: Making genome-scale phylogenetics accessible to all","volume":"31","author":"Thomas","year":"2022","journal-title":"Protein Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/cpz1.90","article-title":"Gene Set Knowledge Discovery with Enrichr","volume":"1","author":"Xie","year":"2021","journal-title":"Curr. Protoc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"D587","DOI":"10.1093\/nar\/gkac963","article-title":"KEGG for taxonomy-based analysis of pathways and genomes","volume":"51","author":"Kanehisa","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/jcb.25549","article-title":"HMGB1 osteo-modulatory action on osteosarcoma SaOS-2 cell line: An integrated study from biochemical and -omics approaches","volume":"117","author":"Martinotti","year":"2016","journal-title":"J. Cell. Biochem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jprot.2016.02.021","article-title":"The secretome signature of malignant mesothelioma cell lines","volume":"145","author":"Manfredi","year":"2016","journal-title":"J. Proteom."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: Protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res."}],"container-title":["Data"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-5729\/8\/12\/177\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:29:55Z","timestamp":1760131795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-5729\/8\/12\/177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["data8120177"],"URL":"https:\/\/doi.org\/10.3390\/data8120177","relation":{},"ISSN":["2306-5729"],"issn-type":[{"type":"electronic","value":"2306-5729"}],"subject":[],"published":{"date-parts":[[2023,11,24]]}}}